Biovie (BIVI) Common Equity (2013 - 2026)
Biovie (BIVI) posted Common Equity of $15.6 million for Q1 2026, down 18.98% sequentially from $19.3 million in Q4 2025, and down 28.46% YoY from $21.8 million in Q1 2025.
Biovie (BIVI) Common Equity (2013 - 2026) Analysis & Trends
Biovie has reported Common Equity for 14 years, with the latest figure at $15.6 million in Q1 2026.
- Quarterly Common Equity fell 28.46% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.6 million (down 28.46% YoY) and the FY2025 annual result came in at $19.0 million, up 22.61% from the prior year.
- Common Equity fell to $15.6 million in Q1 2026 per BIVI's latest filing, from $19.3 million in the prior quarter.
- Over five years, Common Equity peaked at $26.1 million in Q4 2022 and troughed at $3.7 million in Q2 2022.
- A 5-year average of $15.9 million and a median of $15.6 million in 2026 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 317.88% in 2023, down 71.26% in 2023.
- Over 5 years, Common Equity stood at $26.1 million in 2022, then tumbled by 71.26% to $7.5 million in 2023, then jumped by 219.34% to $23.9 million in 2024, then fell by 19.47% to $19.3 million in 2025, then retreated by 18.98% to $15.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $15.6 million, $19.3 million, and $24.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.79 Bn |
| 10 | Biovie | 13.91 Mn | 13.91 Mn | - | 10.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.27 Mn |
| Mar 31, 2026 | 15.61 Mn |
| Dec 31, 2025 | 19.27 Mn |
| Sep 30, 2025 | 24.92 Mn |
| Jun 30, 2025 | 19.01 Mn |
| Mar 31, 2025 | 21.82 Mn |
| Dec 31, 2024 | 23.92 Mn |
| Sep 30, 2024 | 14.07 Mn |
| Jun 30, 2024 | 15.51 Mn |
| Mar 31, 2024 | 18.93 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Sep 30, 2023 | 7.55 Mn |
| Jun 30, 2023 | 15.34 Mn |
| Mar 31, 2023 | 21.72 Mn |
| Dec 31, 2022 | 26.07 Mn |
| Sep 30, 2022 | 5.96 Mn |
| Jun 30, 2022 | 3.67 Mn |
| Mar 31, 2022 | 9.95 Mn |
| Dec 31, 2021 | 16.07 Mn |
| Sep 30, 2021 | 20.23 Mn |